cRD2D3

cRD2D3 is a cyclic, all-D-enantiomeric peptide developed for the treatment of Alzheimer's disease. It is a structural variant of the linear peptide RD2D3, both of which are derivatives of the D3 peptide identified via mirror-image phage display. cRD2D3 is specifically engineered to target and eliminate toxic amyloid-beta (Aβ) oligomers, which are considered key drivers of neurodegeneration. The use of D-amino acids provides the peptide with high proteolytic stability, while the cyclization was intended to increase binding affinity and potency. Although cRD2D3 showed enhanced in vitro potency compared to its linear counterpart, preclinical in vivo studies in Tg-SwDI mice indicated that the linear RD2D3 was more effective at improving cognitive and phenotypic deficits.

Other names

cyclic RD2D3